Showing results (511-520 of 601) with videos related to
Sort By:
Pageof 61
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 16, 2015
Placebo-controlled study in neuromyelitis optica-Ethical and design considerationsBruce Ac Cree, Jeffrey L Bennett, Mark Sheehan, et al.Lancet (London, England)|February 1, 2016
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trialFred Lublin, David H Miller, Mark S Freedman, et al.Annals of Neurology|November 25, 2024
Different Treatment Outcomes of Multiple Sclerosis Patients Receiving Ocrelizumab or OfatumumabSven G Meuth, Stephanie Wolff, Anna Mück, et al.Journal of Neurology, Neurosurgery, and Psychiatry|May 23, 2023
Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorderOrhan Aktas, Hans-Peter Hartung, Michael A Smith, et al.Multiple Sclerosis Journal - Experimental, Translational and Clinical|January 9, 2023
Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studiesColin M Dayan, Beatriz Lecumberri, Ilaria Muller, et al.The Lancet. Neurology|March 17, 2018
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extensionRaju Kapoor, Pei-Ran Ho, Nolan Campbell, et al.Neurology|September 4, 2016
Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MSDouglas L Arnold, Elizabeth Fisher, Vesna V Brinar, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|November 5, 2025
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Final analysis of the DAYBREAK open-label extension trialKrzysztof W Selmaj, Lawrence Steinman, Giancarlo Comi, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|July 9, 2021
Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension studyHans-Peter Hartung, Tobias Derfuss, Bruce Ac Cree, et al.The New England Journal of Medicine|August 24, 2022
Ublituximab versus Teriflunomide in Relapsing Multiple SclerosisLawrence Steinman, Edward Fox, Hans-Peter Hartung, et al.Pageof 61